Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ: RARE )

44.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 704
Open 44.85
Bid (Size) 17.94 (2)
Ask (Size) 45.30 (2)
Prev. Close 44.85
Today's Range 44.85 - 44.85
52wk Range 37.02 - 60.37
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire

Performance

YTD
+8.99%
+8.99%
1 Month
+2.51%
+2.51%
3 Month
-18.19%
-18.19%
6 Month
-0.47%
-0.47%
1 Year
+2.84%
+2.84%

More News

Read More
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
Via Benzinga
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
Via Benzinga
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
Via Benzinga
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
Via Benzinga
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
Via Benzinga
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in Investor Conferences in December
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
Via Benzinga
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in Investor Conferences in September
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.